Study of Three Endpoints to Assess the Benefit of Rehabilitation in Patients With Advanced Non-small Cell Lung Cancer Controlled After at Least 6 Months of Systemic Treatment

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Grenoble

About this trial

The objective of this study is to identify an outcome that is relevant for assessing the benefit of rehabilitation in patients with advanced or metastatic non-small cell lung cancer whose disease has been stable or responding for at least 6 months with systemic treatment.

Many people living with lung cancer experience asthenia, which reduces daily activity, independence, and quality of life.

Regular physical activity (PA) is recommended for the management of all chronic diseases, including cancer. PA can be done independently by the patient or supervised by adapted physical activity instructors (EAPA) at home or in a day hospital (HDJ) in medical and rehabilitation care departments (SMR), where it is covered by social security.

Rehabilitation program and physical activity may help improve strength, function, and social participation, for patients with non-small cell lung cancer .

In this study, patients will participate in a 3-month rehabilitation program. We will measure quality of life, hand grip strength, and the Five Times Sit to Stand Test, before and after the program. Other measures will include daily step counts, nutrition, overall health status, continuation of cancer treatment, program adherence, and participant satisfaction.

About 63 participants will be recruited in several hospitals, including CHUGA, CHMS and CHANGE. This patients will be able to choose a program that suits them and is available as part of they care. We are expecting 50 patients to participate in one of the rehabilitation program.

The main goal is to identify the most useful outcomes to assess in future studies that will compare different rehabilitation approaches for people with lung cancer.

Eligibility criteria

Qualifiers

Adult patients treated for NSCLC at CHUGA, CHMS, or CHANGE

Locally advanced or metastatic NSCLC

Tumor disease controlled for at least 6 months following any type of anti-tumor treatment

ECOG Performance Status 0 to 2

Disqualifiers

Initial management of the tumor disease started ≥ 2 years ago

Residual toxicity of grade ≥ 2

Estimated life expectancy less than 6 months (at the discretion of the investigator)

Patient with an absolute contraindication to physical activity at the time of consultation (e.g., unstable angina; acute intercurrent event...)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

63 Participants
are grouped into 1 trial group

Locations

3
CH Métropole Savoie73 100, ChambéryChambéry, France
Centre Hospitalier Annecy Genevois74370, Annecy France
CHU Grenoble Alpes38043, Grenoble France

Sponsors and collaborators

University Hospital, Grenoble

Lead sponsor